|
 The company said on Tuesday its decision to release preclinical data
from more than 50 of its medicines was unprecedented in scale and
would help accelerate the hunt for synergistic tumor-fighting drug
combinations.
The crowd sourcing initiative is being run as part of the DREAM
Challenge, an open innovation non-profit biology project in which
scientists pool ideas and crunch data.
AstraZeneca's decision to make a large data set available to outside
researchers is a further example of the drugs industry exploring
ways to share research at an early pre-competitive stage.
The data includes around 10,000 tested combinations measuring the
ability of drugs to destroy cancer cell lines from different tumor
types and it will be matched with genomic information from the
Wellcome Trust Sanger Institute.
Scientists with winning predictions for the best new cancer drug
combinations will have their ideas submitted for publication in the
journal Nature Biotechnology.
[to top of second column] |
(Reporting by Ben Hirschler, editing by Louise Heavens)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
